This article explores the pros and cons of integrated versus standalone outsourcing services based on an industry-wide survey conducted by Pharma Intelligence in partnership with Syngene.

According to the survey, the pharmaceutical industry is shifting toward integrated outsourcing for drug development to streamline processes, reduce costs, and accelerate timelines. It also reveals that nearly 50% of companies favor integrated outsourcing over standalone projects. Drug developers also see integrated partnerships as a strategic advantage, particularly in oncology, neurology, and immune disorders, where speed to market is critical.

Syngene’s full-spectrum solutions—from discovery to commercial manufacturing—position it as a preferred partner for companies seeking efficiency, flexibility, and regulatory compliance. Further, its proprietary drug discovery platform, SynVent, enables fully integrated therapeutic drug discovery and development across small molecules, new modalities, and biologics.